drugset

drugset / Trial / NCT00686439

Adalimumab for Inflammatory Osteoarthritis

NCT00686439 ↗

Phase 1/2 Completed 20 enrolled University of Alberta

Non-randomizedSingle-groupOpen-labelTreatment

Summary

We will conduct a pilot study of the effectiveness of adalimumab for inflammatory osteoarthritis.

Timeline

Start: 2008-06
Primary completion: 2010-11
Completion: 2010-11

Publications

Maksymowych WP, Russell AS, Chiu P, Yan A, Jones N, Clare T, Lambert RG. Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee. Arthritis Res Ther. 2012 Oct 4;14(5):R206. doi: 10.1186/ar4044.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adalimumab	Monoclonal antibody	40 mg	Subcutaneous

Indications